CEO: John Burt

Advent Contact: Raj Parekh

Novel hormone analogues for appetite suppression

Thiakis was founded in 2004 to develop novel analogues of naturally occurring hormones for the treatment of obesity and co-morbidities based on the research of Professor Steve Bloom.

Advent invested in the Series A in 2006. Thiakis was acquired by Wyeth in 2008 in a transaction worth up to $150m.